BIOMAT Database Logo BIOMAT Database Logo

An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. 1995

T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

The AML1 gene on chromosome 21 is disrupted in the (8;21)(q22;q22) and (3;21)(q26;q22) translocations associated with myelogenous leukemias and encodes a DNA binding protein. From the AML1 gene, two representative forms of proteins, AML1a and AML1b, are produced by alternative splicing. Both forms have a DNA binding domain but, unlike AML1b, AML1a lacks a putative transcriptional activation domain. Here we demonstrate that overexpressed AML1a totally suppresses granulocytic differentiation and stimulates cell proliferation in 32Dcl3 murine myeloid cells treated with granulocyte colony-stimulating factor. These effects of AML1a were canceled by the concomitant overexpression of AML1b. Such biological phenomena could be explained by our observations that (i) AML1a, which on its own has no effects as a transcriptional regulator, dominantly suppresses transcriptional activation by AML1b, and (ii) AML1a exhibits the higher affinity for DNA binding compared with AML1b. These antagonistic actions could be important in leukemogenesis and/or myeloid cell differentiation because more than half of myelogenous leukemia patients showed an increase in the relative amounts of AML1a.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia.
July 1995, Nucleic acids research,
T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
A large variety of alternatively spliced and differentially expressed mRNAs are encoded by the human acute myeloid leukemia gene AML1.
March 1996, DNA and cell biology,
T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
Expression of the human acute myeloid leukemia gene AML1 is regulated by two promoter regions.
March 1996, Proceedings of the National Academy of Sciences of the United States of America,
T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia.
May 2007, Blood,
T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin.
September 2004, Proceedings of the National Academy of Sciences of the United States of America,
T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
A Case of Acute Mixed Cell Leukemia Resembling AML1-ETO Positive Acute Myeloid Leukemia.
April 2023, Clinical laboratory,
T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value.
December 2000, British journal of haematology,
T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
Regulation of c-fos gene transcription and myeloid cell differentiation by acute myeloid leukemia 1 and acute myeloid leukemia-MTG8, a chimeric leukemogenic derivative of acute myeloid leukemia 1.
March 1999, FEBS letters,
T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
AML1-ETO inhibits acute myeloid leukemia immune escape by CD48.
April 2021, Leukemia & lymphoma,
T Tanaka, and K Tanaka, and S Ogawa, and M Kurokawa, and K Mitani, and J Nishida, and Y Shibata, and Y Yazaki, and H Hirai
Cell differentiation in acute myeloid leukemia.
July 1996, European journal of haematology,
Copied contents to your clipboard!